CareDx, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CareDx, Inc. (CDNA) on September 15, 2021. The report discloses the appointment of a new director to the Company's Board of Directors and related compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation rather than financial performance.
Material Changes
The primary material change reported is the appointment of Arthur A. Torres as a Class III director, effective September 15, 2021. Senator Torres was also appointed to the Nominating and Corporate Governance Committee. No financial material changes were reported in this document.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or management commentary regarding business operations in this filing. The document details the new director's background, including his roles as Vice Chair of the California Institute for Regenerative Medicine (CIRM) and the One Legacy Foundation, and his prior service in the California State Senate and Assembly. The filing outlines the specific compensation package for Senator Torres:
- Annual Cash Retainer: $40,000, paid quarterly (electable as cash or stock).
- Initial Stock Option: Grant date fair value of $150,000, vesting monthly over three years.
- Initial Restricted Stock Units (RSUs): Grant date fair value of $150,000, vesting in three equal annual installments.
- Annual Automatic Grants: Upon each annual stockholder meeting, an option with a fair value of $100,000 and RSUs with a fair value of $100,000.
The Company also entered into a standard indemnification agreement with Senator Torres. No related party transactions were reported.
Investor Verification Checklist
- Verify the effective date of Senator Torres' board service (September 15, 2021).
- Confirm the total annualized compensation value for the new director ($40,000 cash + $250,000 initial equity + $200,000 annual recurring equity).
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Check subsequent filings for any changes to the Board composition or compensation policy.